Results 21 to 30 of about 1,413,485 (300)
Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen [PDF]
, 2007 Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.Objective: To compare the cost ...
B Dahlof +8 more
core +1 more source
Фармакоэкономика, 2018 The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e.
T. S. Teptsova +5 more
doaj +1 more source
Economic evaluation of laparoscopic surgery for colorectal cancer [PDF]
, 2007 Objectives: To assess the cost-effectiveness of laparoscopic surgery compared with open surgery for the treatment of colorectal cancer. Methods: A Markov model was developed to model cost-effectiveness over 25 years.
Aberdeen Health Technology Assessment Group +3 more
core +1 more source
Diseases, 2023 Background: Respiratory syncytial virus (RSV) is one of the leading causes of pediatric hospitalizations, mainly in children under 2 years of age. Hospitalization affects the caregivers’ quality of life (QoL).
August Wrotek +2 more
doaj +1 more source
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]
, 2003 OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K. +6 more
core +2 more sources
A technique for approximating transition rates from published survival analyses
Cost Effectiveness and Resource Allocation, 2019 Background Quality-adjusted-life-years (QALYs) are used to concurrently quantify morbidity and mortality within a single parameter. For this reason, QALYs can facilitate the discussion of risks and benefits during patient counseling regarding treatment ...
Markian A. Pahuta +4 more
doaj +1 more source
BMC Public Health, 2022 Background The burden of chronic diseases is rapidly rising, both in terms of morbidity and mortality. This burden is disproportionally carried by socially disadvantaged population subgroups.
Lisa Van Wilder +6 more
doaj +1 more source
El labrador: Año I Número 3 - (14/03/22) [PDF]
, 1922 BACKGROUND: Use of everolimus-eluting stents (EES) has proven to be clinically effective and safe in patients with ST-segment elevation myocardial infarction but it remains unclear whether it is cost-effective compared to bare-metal stents (BMS) in the ...
Ademi, Zanfina +17 more
core +9 more sources
Measuring Quality-Adjusted Life-Years When Health Fluctuates [PDF]
Value in Health, 2020 Recurrent fluctuations in health states can occur as a result of long-term conditions with episodic symptoms or through side effects of cycles of treatment. Fluctuations and associated duration of symptoms can be predictable (eg, side effects of chemotherapy treatment) or unpredictable (eg, relapse in multiple sclerosis). Such recurrent fluctuations in
Sanghera, Sabina, Coast, Joanna
openaire +4 more sources
Journal of the Formosan Medical Association, 2013 The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho +8 more
doaj +1 more source